Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01836549 · ClinicalTrials.gov registry record · Phase 2
Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors
A Phase 2 study, sponsored by Pediatric Brain Tumor Consortium.
- Terminated
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
NCT01836549 is a Phase 2 study that was terminated before completion, run by Pediatric Brain Tumor Consortium. The registered enrollment target is 43 participants.
The verdict
NCT01836549, a Phase 2 study, was terminated before completion, sponsored by Pediatric Brain Tumor Consortium.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
Study Summary
This molecular biology and phase II trial studies how well imetelstat sodium works in treating younger patients with recurrent or refractory brain tumors. Imetelstat sodium may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Interventions
- DRUG imetelstat sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2013-03 |
| Est. Completion | 2016-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01836549
The ClinicalTrials.gov registry entry for NCT01836549 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pediatric Brain Tumor Consortium, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which imetelstat sodium is the first listed.
NCT01836549 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01836549 about?
NCT01836549 is a clinical study titled "Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors". This molecular biology and phase II trial studies how well imetelstat sodium works in treating younger patients with recurrent or refractory brain tumors. Imetelstat sodium may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
What is the current status of trial NCT01836549?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2013-03. Estimated completion is 2016-04.
What interventions are being tested in trial NCT01836549?
The interventions under investigation include: imetelstat sodium (DRUG).
Who is sponsoring clinical trial NCT01836549?
This trial is sponsored by Pediatric Brain Tumor Consortium, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.